Study M613
Study name | Hamilton PJ 2020 |
Title | Chronic stress and antidepressant treatment alter purine metabolism and beta oxidation within mouse brain and serum |
Overall design | The aim of this study was to perform metabolomic, lipidomic, and proteomic profiling on serum plus several brain regions (ventral hippocampus, nucleus accumbens, and medial prefrontal cortex) of susceptible, resilient, and unstressed control mice. Chronic social defeat stress (CSDS) model of depression was established. To identify how commonly used tricyclic antidepressants impact the molecular composition in these tissues, stress-exposed mice were then treated with imipramine. C57BL/6 J mice were divided into the following 4 groups: (1) control group (no stress for 10 days), (2) CSDS group (social defeat stress for 10 days), (3) CSDS + vehicle group (social defeat stress for 10 days, and then treated with vehicle for 14 days after stress), and (4) CSDS + imipramine group (social defeat stress for 10 days, and then treated with imipramine for 14 days after stress, i.p. twice-daily at the dose of 10 mg/kg). Stressed mice were characterized as susceptible (social interaction ratio < 1) or resilient (social interaction ratio > 1). |
Study Type | Type1; Type2; |
Data available | |
Organism | Mouse; C57BL/6 J mouse; |
Categories of depression | Animal model; Social defeat model; Social defeat model; |
Criteria for depression | Social interaction test |
Sample size | N/A |
Tissue | Central; Brain; Nucleus accumbens; Central; Brain; Medial prefrontal cortex; Peripheral; Blood; Serum; Central; Brain; Ventral hippocampus; |
Platform | MS-based; GC-MS: not reported; MS-based; LC-MS: not reported; |
PMID | |
DOI | |
Citation | Hamilton PJ, Chen EY, Tolstikov V, et al. Chronic stress and antidepressant treatment alter purine metabolism and beta oxidation within mouse brain and serum. Sci Rep. 2020;10(1):18134. |
Metabolite | Gamma-Aminobutyric acid; 3-Hydroxybutyric acid; Myristic acid; Imidazoleacetic acid; Methylimidazoleacetic acid; L-Leucine; L-Threonine; Hippuric acid; Succinic acid; Oxalic acid; D-Glucose; L-Kynurenine; Cholic acid; LysoPC(16:0); Propionylcarnitine; Indoxyl sulfate; Hypoxanthine; Uric acid; Xanthine; DOPA; Indole-3-carboxylic acid; Fumaric acid; Ethanolamine; Pyruvic acid; Betaine; N-Acetylglutamine; 2-Hydroxybutyric acid; Gluconic acid; Xanthosine; Cholesterol; Cyclic AMP; Glycolic acid; Dihydroxyacetone phosphate; Glucose 1-phosphate; NAD; DL-2-Aminooctanoic acid; Hydroxyisocaproic acid; Orotidylic acid; L-Acetylcarnitine; Taurodeoxycholic acid; Pyrophosphate; Oxidized glutathione; Alpha-ketoisovaleric acid; 2-Ketohexanoic acid; Glycerophosphocholine; D-Ribose 5-phosphate; Aminoadipic acid; N-Acetyl-glucosamine 1-phosphate; Adenine; Sucrose; Quinolinic acid; Nicotinic acid; Malonic acid; LysoPC(18:1); LysoPC(18:2); Oleoylcarnitine; TG(60:12); 5-Aminopentanoic acid; Indoleacrylic acid; Putrescine; Glutathione; Acetylphosphate; AICAR; ADP; LysoPE(18:1); LysoPE(20:3); PE(34:2); LysoPC(16:1/0:0); LysoPE(16:1); Hexanoylcarnitine; PE(O-36:5); L-Alpha-aminobutyric acid; 2-Keto-L-gluconate; Cytidine monophosphate; Guanidoacetic acid; Phosphate; O-Phosphoethanolamine; SM(d18:1/16:0); O-Phosphotyrosine; Glucosamine; Methionine sulfoxide; Hydroxybutyrylcarnitine; L-Palmitoylcarnitine; p-Aminobenzoic acid; LysoPC(20:4); LysoPC(20:5); Homocysteine; Sphingosine 1-phosphate; 3-Methylhistidine; Thiamine; Gluconolactone; Cer(d18:1/16:0); Cer(d18:1/22:0); Cer(d18:1/24:1); PE(36:1); LysoPE(22:6); LysoPC(20:0/0:0); LysoPE(20:4); PE(38:6); DG(36:1); TG(40:0); TG(44:0); TG(46:1); TG(48:0); TG(52:1); TG(52:3); TG(54:2); TG(54:4); TG(56:1); TG(58:5); PE(O-36:3); PE(O-34:2); Citronellyl anthranilate; Cysteinylglycine; 2-Ketobutyric acid; Lactose; LysoPC(22:5); LysoPC(20:3); Succinyladenosine; FAD; SM(d18:2/24:0); |
